{"nctId":"NCT01918332","briefTitle":"Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia","startDateStruct":{"date":"2012-04"},"conditions":["Hypertension,","Hyperlipidemia"],"count":168,"armGroups":[{"label":"Valsartan 160mg, Rosuvastatin 20mg","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan 160mg","Drug: Rosuvastatin 20mg"]},{"label":"Valsartan 160mg, Rosuvastatin 20mg placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Valsartan 160mg","Drug: Rosuvastatin 20mg placebo"]},{"label":"Valsartan 160mg placebo, Rosuvastatin 20mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rosuvastatin 20mg","Drug: Valsartan 160mg placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Valsartan 160mg placebo","Drug: Rosuvastatin 20mg placebo"]}],"interventions":[{"name":"Valsartan 160mg","otherNames":["Diovan"]},{"name":"Rosuvastatin 20mg","otherNames":["Crestor"]},{"name":"Valsartan 160mg placebo","otherNames":[]},{"name":"Rosuvastatin 20mg placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patient aged 20-80 years who has hypertension and hyperlipidemia\n2. Patient who has a Hypertension\n3. Patient who has a Hyperlipidemia according to NCEP-ATP III guideline(2004)\n4. Patient who signed the Informed Consent Form after receiving an explanation on the purpose, methods, and effect of the study\n\nExclusion Criteria:\n\n1. If blood pressure and fasting serum lipid level measured at screening and Visit 2 (0 week) satisfy the following criteria 1) sitSBP≥180mmHg or sitDBP≥110mmHg (For high risk group, sitSBP≥ 160mmHg or sitDBP ≥100mmHg ) 2) LDL-C\\>250mg/dL , or TG≥ 400mg/dL\n2. If sitSBP difference between the right and left arms \\>20mmHg or sitDBP difference between the right and left arms \\> 10mmHg at screening\n3. When blood pressure is repeatedly measured from the selected arm at screening, if sitSBP difference ≥ 20mmHg or sitDBP difference ≥10mmHg\n4. Patient with orthostatic hypotension accompanying symptoms at screening (decrease in sitDBP ≥10mmHg or decrease in sitSBP ≥ 20mmHg )","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"sitDBP Changes at Week 8 From Baseline","description":"sitDBP changes of the valsartan 160mg and valsartan placebo groups at Week 8 from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.24","spread":null},{"groupId":"OG001","value":"-2.9","spread":null}]}]}]},{"type":"PRIMARY","title":"LDL-C Percentage Changes at Week 8 From Baseline","description":"LDL-C percentage changes of the rosuvastatin 20mg and rosuvastatin placebo groups at Week 8 from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.91","spread":null},{"groupId":"OG001","value":"-2.38","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":43},"commonTop":["headache","dyspepsia","alanine aminotransferase increased","dizziness","nausea"]}}}